AbbVie must undercut Gilead in hep C following EU approval
This article was originally published in Scrip
Executive Summary
AbbVie has won European approval for its hepatitis C regimen, Viekirax (ombitasvir plus paritaprevir plus ritonavir) and Exviera (dasabuvir), but the company is under pressure to undercut competitor Gilead on pricing if it is to gain market share.